Cancer Letters
Volume 297, Issue 1 , Pages 31-41 , 1 November 2010

Leukemia inhibitory factor can mediate Ras/Raf/MEK/ERK-induced growth inhibitory signaling in medullary thyroid cancer cells

Received 16 February 2010 ,Revised 14 April 2010 ,Accepted 27 April 2010.

References 

  1. Kouvaraki MA, Shapiro SE, Perrier ND, Cote GJ, Gagel RF, Hoff AO, et al. RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid. 2005;15:531–544
  2. Ichihara M, Murakumo Y, Takahashi M. RET and neuroendocrine tumors. Cancer Letters. 2004;204:197–211
  3. Schlumberger M, Carlomagno F, Baudin E, Bidart JM, Santoro M. New therapeutic approaches to treat medullary thyroid carcinoma. Nature Clinical Practice. 2008;4:22–32
  4. Mooi WJ, Peeper DS. Oncogene-induced cell senescence – halting on the road to cancer. The New England journal of medicine. 2006;355:1037–1046
  5. Braig M, Schmitt CA. Oncogene-induced senescence. Putting the brakes on tumor development. Cancer Research. 2006;66:2881–2884
  6. Nakagawa T, Mabry M, De Bustros A, Ihle JN, Nelkin BD, Baylin SB. Introduction of v-Ha-ras oncogene induces differentiation of cultured human medullary thyroid carcinoma cells. Proceedings of the National Academy of Sciences of the United States of America. 1987;84:5923–5927
  7. Wood KW, Qi H, D’Arcangelo G, Armstrong RC, Roberts TM, Halegoua S. The cytoplasmic raf oncogene induces a neuronal phenotype in PC12 cells: a potential role for cellular raf kinases in neuronal growth factor signal transduction. Proceedings of the National Academy of Sciences of the United States of America. 1993;90:5016–5020
  8. Carson EB, McMahon M, Baylin SB, Nelkin BD. Ret gene silencing is associated with Raf-1-induced medullary thyroid carcinoma cell differentiation. Cancer Research. 1995;55:2048–2052
  9. Carson-Walter EB, Smith DP, Ponder BA, Baylin SB, Nelkin BD. Post-transcriptional silencing of RET occurs, but is not required, during raf-1 mediated differentiation of medullary thyroid carcinoma cells. Oncogene. 1998;17:367–376
  10. Ravi RK, Weber E, McMahon M, Williams JR, Baylin S, Mal A, et al. Activated Raf-1 causes growth arrest in human small cell lung cancer cells. The Journal of Clinical Investigation. 1998;101:153–159
  11. Ravi RK, Thiagalingam A, Weber E, McMahon M, Nelkin BD, Mabry M. Raf-1 causes growth suppression and alteration of neuroendocrine markers in DMS53 human small-cell lung cancer cells. American Journal of Respiratory Cell and Molecular Biology. 1999;20:543–549
  12. Fanton CP, McMahon M, Pieper RO. Dual growth arrest pathways in astrocytes and astrocytic tumors in response to Raf-1 activation. The Journal of Biological Chemistry. 2001;276:18871–18877
  13. Park JI, Strock CJ, Ball DW, Nelkin BD. The Ras/Raf/MEK/extracellular signal-regulated kinase pathway induces autocrine-paracrine growth inhibition via the leukemia inhibitory factor/JAK/STAT pathway. Molecular and Cellular Biology. 2003;23:543–554
  14. Park JI, Powers JF, Tischler AS, Strock CJ, Ball DW, Nelkin BD. GDNF-induced leukemia inhibitory factor can mediate differentiation via the MEK/ERK pathway in pheochromocytoma cells derived from nf1-heterozygous knockout mice. Experimental Cell Research. 2005;303:79–88
  15. Vaccaro A, Chen H, Kunnimalaiyaan M. In-vivo activation of Raf-1 inhibits tumor growth and development in a xenograft model of human medullary thyroid cancer. Anti-Cancer Drugs. 2006;17:849–853
  16. Hong SK, Yoon S, Moelling C, Arthan D, Park JI. Noncatalytic function of ERK1/2 can promote Raf/MEK/ERK-mediated growth arrest signaling. The Journal of Biological Chemistry. 2009;284:33006–33018
  17. Auernhammer CJ, Melmed S. Leukemia-inhibitory factor-neuroimmune modulator of endocrine function. Endocrine Reviews. 2000;21:313–345
  18. Metcalf D. The unsolved enigmas of leukemia inhibitory factor. Stem cells (Dayton, Ohio). 2003;21:5–14
  19. Choubey D, Deka R, Ho SM. Interferon-inducible IFI16 protein in human cancers and autoimmune diseases. Frontiers in Bioscience. 2008;13:598–608
  20. Luan Y, Lengyel P, Liu CJ. P204, a p200 family protein, as a multifunctional regulator of cell proliferation and differentiation. Cytokine & Growth Factor Reviews. 2008;
  21. Kim EJ, Park JI, Nelkin BD. IFI16 is an essential mediator of growth inhibition, but not differentiation, induced by the leukemia inhibitory factor/JAK/STAT pathway in medullary thyroid carcinoma cells. The Journal of Biological Chemistry. 2005;280:4913–4920
  22. Samuels ML, Weber MJ, Bishop JM, McMahon M. Conditional transformation of cells and rapid activation of the mitogen-activated protein kinase cascade by an estradiol-dependent human raf-1 protein kinase. Molecular and Cellular Biology. 1993;13:6241–6252
  23. Kotanides H, Moczygemba M, White MF, Reich NC. Characterization of the interleukin-4 nuclear activated factor/STAT and its activation independent of the insulin receptor substrate proteins. The Journal of Biological Chemistry. 1995;270:19481–19486
  24. Park JI, Strock CJ, Ball DW, Nelkin BD. Interleukin-1beta can mediate growth arrest and differentiation via the leukemia inhibitory factor/JAK/STAT pathway in medullary thyroid carcinoma cells. Cytokine. 2005;29:125–134
  25. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proceedings of the National Academy of Sciences of the United States of America. 1998;95:2509–2514
  26. Klesse LJ, Meyers KA, Marshall CJ, Parada LF. Nerve growth factor induces survival and differentiation through two distinct signaling cascades in PC12 cells. Oncogene. 1999;18:2055–2068
  27. Vindelov LL, Christensen IJ, Nissen NI. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry. 1983;3:323–327
  28. Sippel RS, Carpenter JE, Kunnimalaiyaan M, Chen H. The role of human achaete-scute homolog-1 in medullary thyroid cancer cells. Surgery. 2003;134:866–871
  29. Takahashi M, Buma Y, Taniguchi M. Identification of the ret proto-oncogene products in neuroblastoma and leukemia cells. Oncogene. 1991;6:297–301
  30. Mansour SJ, Matten WT, Hermann AS, Candia JM, Rong S, Fukasawa K, et al. Transformation of mammalian cells by constitutively active MAP kinase kinase. Science. 1994;265:966–970
  31. Woods D, Parry D, Cherwinski H, Bosch E, Lees E, McMahon M. Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Molecular and Cellular Biology. 1997;17:5598–5611
  32. Zhu J, Woods D, McMahon M, Bishop JM. Senescence of human fibroblasts induced by oncogenic Raf. Genes & Development. 1998;12:2997–3007
  33. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, et al A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proceedings of the National Academy of Sciences of the United States of America. 1995;92:9363–9367
  34. Bromberg JF, Horvath CM, Besser D, Lathem WW, Darnell JE. Stat3 activation is required for cellular transformation by v-src. Molecular and Cellular Biology. 1998;18:2553–2558
  35. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, et al. Stat3 as an oncogene. Cell. 1999;98:295–303
  36. Takahashi C, Contreras B, Iwanaga T, Takegami Y, Bakker A, Bronson RT, et al. Nras loss induces metastatic conversion of Rb1-deficient neuroendocrine thyroid tumor. Nature Genetics. 2006;38:118–123
  37. Hasegawa T, Enomoto A, Kato T, Kawai K, Miyamoto R, Jijiwa M, et al. Roles of induced expression of MAPK phosphatase-2 in tumor development in RET-MEN2A transgenic mice. Oncogene. 2008;27:5684–5695
  38. de Groot JW, Plaza Menacho I, Schepers H, Drenth-Diephuis LJ, Osinga J, Plukker JT, et al. Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated RET mutations. Surgery. 2006;139:806–814
  39. Gorla L, Mondellini P, Cuccuru G, Micciche F, Cassinelli G, Cremona M, et al. Proteomics study of medullary thyroid carcinomas expressing RET germ-line mutations: identification of new signaling elements. Molecular Carcinogenesis. 2008;
  40. Morisi R, Celano M, Tosi E, Schenone S, Navarra M, Ferretti E, et al. Growth inhibition of medullary thyroid carcinoma cells by pyrazolo-pyrimidine derivates. Journal of Endocrinological Investigation. 2007;30:RC31–RC34
  41. Plaza-Menacho I, Mologni L, Sala E, Gambacorti-Passerini C, Magee AI, Links TP, et al. Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting. The Journal of Biological Chemistry. 2007;282:29230–29240
  42. van Weering DH, Moen TC, Braakman I, Baas PD, Bos JL. Expression of the receptor tyrosine kinase Ret on the plasma membrane is dependent on calcium. The Journal of Biological Chemistry. 1998;273:12077–12081
  43. Cagnol S, Chambard JC. ERK and cell death: mechanisms of ERK-induced cell death – apoptosis, Autophagy and senescence. The FEBS Journal. 2009;277:2–21
  44. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nature Reviews. 2004;4:11–22
  45. Farese AM, Myers LA, MacVittie TJ. Therapeutic efficacy of recombinant human leukemia inhibitory factor in a primate model of radiation-induced marrow aplasia. Blood. 1994;84:3675–3678
  46. Kurek JB, Radford AJ, Crump DE, Bower JJ, Feeney SJ, Austin L, et al. LIF (AM424), a promising growth factor for the treatment of ALS. Journal of the Neurological Sciences. 1998;160(Suppl. 1):S106–113
  47. Davis ID, Kiers L, MacGregor L, Quinn M, Arezzo J, Green M, et al. A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy. Clinical Cancer Research. 2005;11:1890–1898
  48. Acosta JC, O’Loghlen A, Banito A, Guijarro MV, Augert A, Raguz S, et al. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell. 2008;133:1006–1018
  49. Kuilman T, Michaloglou C, Vredeveld LC, Douma S, van Doorn R, Desmet CJ, et al. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell. 2008;133:1019–1031
  50. Wajapeyee N, Serra RW, Zhu X, Mahalingam M, Green MR. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell. 2008;132:363–374
  51. Wajapeyee N, Kapoor V, Mahalingam M, Green MR. Efficacy of IGFBP7 for treatment of metastatic melanoma and other cancers in mouse models and human cell lines. Molecular Cancer Therapeutics. 2009;8:3009–3014

PII: S0304-3835(10)00236-3

doi: 10.1016/j.canlet.2010.04.021

Cancer Letters
Volume 297, Issue 1 , Pages 31-41 , 1 November 2010

Article Tools

* Image Usage & Resolution